This response was dose-dependent and specific, as 0.74 MBq of [177Lu]-Lu ofatumumab and 8.51 MBq of [177Lu]-IgG did not extend survival or prevent tumor-cell proliferation. This evidence concerns the gene BCAM and neoplasm.